THEOBID JR Drug Patent Profile
✉ Email this page to a colleague
When do Theobid Jr patents expire, and what generic alternatives are available?
Theobid Jr is a drug marketed by Whitby and is included in one NDA.
The generic ingredient in THEOBID JR is theophylline. There are thirty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theobid Jr
A generic version of THEOBID JR was approved as theophylline by RHODES PHARMS on September 1st, 1982.
Summary for THEOBID JR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | THEOBID JR at DailyMed |
US Patents and Regulatory Information for THEOBID JR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Whitby | THEOBID JR. | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 087854-001 | Mar 20, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |